Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | VHL | P40337 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25511293 | 0.84 | KMT2A (0.41) | KMT2AHDAC1HDAC6RAB9AMAPT | |
| SCHEMBL18119788 | 0.84 | KMT2A (0.56) | KMT2AHDAC1HDAC6RAB9AMAPT | |
| SCHEMBL12103905 | 0.83 | KMT2A (0.51) | KMT2AHDAC1HDAC6RAB9AMAPT | |
| SCHEMBL26157078 | 0.83 | ERCC1 (0.50) | KMT2AHDAC1MAPTALDH1A1KDM4E | |
| SCHEMBL15748044 | 0.82 | CYP3A4 (0.55) | KMT2AHDAC1HDAC6ALDH1A1HDAC2 | |
| SCHEMBL16384737 | 0.82 | TPSAB1 (0.49) | KMT2AHDAC1HDAC6ALDH1A1HDAC2 | |
| SCHEMBL24633926 | 0.80 | TGM2 (0.56) | HDAC1HDAC6MAPTALDH1A1HDAC2 | |
| SCHEMBL16616006 | 0.80 | NAMPT (0.53) | HDAC1HDAC6MAPTEPHX2NR1H4 | |
| SCHEMBL14677758 | 0.79 | HTT (0.57) | KMT2AALDH1A1KDM4E | |
| SCHEMBL26036197 | 0.79 | TPSAB1 (0.49) | KMT2AHDAC1HDAC6ALDH1A1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4186529-A1 | IMPROVED ANTIBODY-PAYLOAD CONJUGATES (APCS) PREPARED BY SITE-SPECIFIC CONJUGATION UTILIZING GENETIC CODE EXPANSION | Veraxa Biotech GmbH (DE) | 2023-05-31 | — | — | EP | disclosed |
| WO-2023081809-A1 | TRANS-CYCLOOCTENE-MODIFIED BISPECIFIC ANTIBODIES | TAMBO, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-10-22 | — | — | US | disclosed |
| US-20150125904-A1 | PROBE INCORPORATION MEDIATED BY ENZYMES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150125904-A1 | PROBE INCORPORATION MEDIATED BY ENZYMES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-05-07 | — | — | US | disclosed |
| US-8900549-B2 | Compositions and methods for delivering a substance to a biological target | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2014081300-A1 | CHANNEL PROTEIN ACTIVATABLE LIPOSOMES | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081303-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| US-20130302246-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | THE GENERAL HOSPITAL CORPORATION | 2013-11-14 | — | — | US | disclosed |
| WO-2013148189-A1 | PROBE INCORPORATION MEDIATED BY ENZYMES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-03 | — | — | WO | disclosed |
| US-20110268654-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | THE GENERAL HOSPITAL CORPORATION (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | SQLE, CTRL, ENO1 | KMT2A 3934/4885HDAC1 4199/4885HDAC6 4562/4885 |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KIT, JMJD7, TPSB2 | KMT2A 3455/4885HDAC1 3780/4885HDAC6 4274/4885 |
| US-20110268654-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | FCER2, EPCAM, EPHA2 | KMT2A 3935/4885HDAC1 4271/4885HDAC6 2590/4885 |
| US-20130302246-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | FCER2, EPCAM, EPHA2 | KMT2A 3935/4885HDAC1 4271/4885HDAC6 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.